This site is intended for healthcare professionals

NGM Bio reports topline results from 24-week phase IIb ALPINE 2/3 study of aldafermin in NASH.

Read time: 1 mins
Last updated:28th Jun 2021
Published:25th May 2021
NGM Biopharmaceuticals, Inc. reported results from the 24-week Phase IIb ALPINE 2/3 study evaluating aldafermin in 171 patients with biopsy-confirmed non-alcoholic steatohepatitis (NASH) with stage 2 or 3 liver fibrosis (F2/F3).
Condition: Non Alcoholic Steatohepatitis (NASH)
Type: drug
Register for free access to this exclusive healthcare learning resource

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest